Dosage of Tropicil in details
Usual Adult Dose for Refraction
Cycloplegic Refraction:
-Instill 1 or 2 drops of the 1% solution into eye(s); repeat in 5 minutes.
Comment:
-An additional drop may be given if the examination is not done within 20 to 30 minutes.
Use: To produce mydriasis and cycloplegia for diagnostic procedures.
Usual Adult Dose for Pupillary Dilation
Fundoscopy:
-Instill 1 or 2 drops of 0.5% solution into eye(s) 15 or 20 minutes prior to examination.
Comments:
-Heavily pigmented irides may require higher strength or more doses.
Use: To produce mydriasis and cycloplegia for diagnostic procedures.
Usual Pediatric Dose for Refraction
Cycloplegic Refraction:
-Instill 1 or 2 drops of the 1% solution into eye(s); repeat in 5 minutes.
Comment:
-An additional drop may be given if the examination is not done within 20 to 30 minutes.
Use: To produce mydriasis and cycloplegia for diagnostic procedures.
Usual Pediatric Dose for Pupillary Dilation
Fundoscopy:
-Instill 1 or 2 drops of 0.5% solution into eye(s) 15 or 20 minutes prior to examination.
Comments:
-Heavily pigmented irides may require higher strength or more doses.
Use: To produce mydriasis and cycloplegia for diagnostic procedures.
Renal Dose Adjustments
No dosage adjustment is recommended.
Liver Dose Adjustments
No dosage adjustment is recommended.
Dose Adjustments
Use caution in inflamed eyes as hyperemia greatly increases the rate of systemic absorption through the conjunctiva.
Heavily pigmented irides may require higher strength or more doses.
Systemic absorption can be minimized by applying pressure to the lacrimal duct for 1 to 2 minutes after instillation.
Precautions
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
-For topical use only, not for injection
-Contact lenses should be removed before use.
-Wash hands after administration to avoid accidental ingestion.
-Systemic absorption may be minimized by applying pressure to the lacrimal duct for 1 minute after instillation.
Storage requirements:
Store at 8C to 27C (46F to 80F); do not refrigerate; protect from light; keep container tightly closed.
General:
-Patients with heavily pigmented irides may require higher strength or more doses.
-Complete recovery from mydriasis may take up to 24 hours.
Patient advice:
-Patients should be advised to apply pressure to the lacrimal sac for 1 to 3 minutes after instillation, to minimize systemic absorption (especially in children).
-Parents should be warned about oral toxicity with accidental ingestion, and advised to wash their hands and the child's hands after use.
-Patients should be advised to protect eyes from bright light during dilation.
-Patients should be advised not to drive or perform potentially hazardous activities while pupils are dilated.
Tropicil interactions
The risks of using Olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of Olanzapine, caution should be used when Olanzapine is taken in combination with other centrally acting drugs and alcohol.
Because of its potential for inducing hypotension, Olanzapine may enhance the effects of certain antihypertensive agents.
Olanzapine may antagonize the effects of levodopa and dopamine agonists.
The Effect of Other Drugs on Olanzapine — Agents that induce CYP1A2 or glucuronyl transferase enzymes, such as omeprazole and rifampin, may cause an increase in Olanzapine clearance. Inhibitors of CYP1A2 could potentially inhibit Olanzapine clearance. Although Olanzapine is metabolized by multiple enzyme systems, induction or inhibition of a single enzyme may appreciably alter Olanzapine clearance. Therefore, a dosage increase (for induction) or a dosage decrease (for inhibition) may need to be considered with specific drugs.
Charcoal — The administration of activated charcoal (1 g) reduced the Cmax and AUC of oral Olanzapine by about 60%. As peak Olanzapine levels are not typically obtained until about 6 hours after dosing, charcoal may be a useful treatment for Olanzapine overdose.
Cimetidine and Antacids — Single doses of cimetidine (800 mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of Olanzapine.
Carbamazepine — Carbamazepine therapy (200 mg bid) causes an approximately 50% increase in the clearance of Olanzapine. This increase is likely due to the fact that carbamazepine is a potent inducer of CYP1A2 activity. Higher daily doses of carbamazepine may cause an even greater increase in Olanzapine clearance.
Ethanol — Ethanol (45 mg/70 kg single dose) did not have an effect on Olanzapine pharmacokinetics.
Fluoxetine — Fluoxetine (60 mg single dose or 60 mg daily for 8 days) causes a small (mean 16%) increase in the maximum concentration of Olanzapine and a small (mean 16%) decrease in Olanzapine clearance. The magnitude of the impact of this factor is small in comparison to the overall variability between individuals, and therefore dose modification is not routinely recommended.
Fluvoxamine — Fluvoxamine, a CYP1A2 inhibitor, decreases the clearance of Olanzapine. This results in a mean increase in Olanzapine Cmax following fluvoxamine of 54% in female nonsmokers and 77% in male smokers. The mean increase in Olanzapine AUC is 52% and 108%, respectively. Lower doses of Olanzapine should be considered in patients receiving concomitant treatment with fluvoxamine.
Warfarin — Warfarin (20 mg single dose) did not affect Olanzapine pharmacokinetics.
Lithium — Multiple doses of Olanzapine (10 mg for 8 days) did not influence the kinetics of lithium. Therefore, concomitant Olanzapine administration does not require dosage adjustment of lithium.
Valproate —In vivo administration of Olanzapine (10 mg daily for 2 weeks) did not affect the steady state plasma concentrations of valproate. Therefore, concomitant Olanzapine administration does not require dosage adjustment of valproate.
The co-administration of either diazepam or ethanol with Olanzapine potentiated the orthostatic hypotension observed with Olanzapine. Multiple doses of Olanzapine did not affect the pharmacokinetics of theophylline or its metabolites.
References
- DailyMed. "HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- MeSH. "Muscarinic Antagonists". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
- European Chemicals Agency - ECHA. "Tropicamide: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". https://echa.europa.eu/information-o... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Tropicil are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Tropicil. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported frequency of use
No survey data has been collected yetConsumer reported doses
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
